Literature DB >> 19249543

Purification method using iodixanol (OptiPrep)-based density gradient significantly reduces cytokine chemokine production from human islet preparations, leading to prolonged beta-cell survival during pretransplantation culture.

A Mita1, C Ricordi, A Miki, S Barker, A Khan, A Alvarez, Y Hashikura, S Miyagawa, H Ichii.   

Abstract

Purification is one of the most important steps in human islet isolation. Although Ficoll-based density gradients are widely used, OptiPrep-based density gradients are used in few centers. Cytokine/chemokine production from human islet preparations varies widely. Some cytokines/chemokines have been reported to have adverse effects on human islet preparations. Control of cytokine/chemokine production may be a key to improve islet quality and quantity, leading to better transplantation outcomes. The aim of the present study was to investigate the effects on islet preparations of purification methods using various density gradients on viability, cellular composition, and proinflammatory cytokine/chemokine production. After the digestion phase, the extracts were divided into 2 groups for purification using a semiautomated cell processor with Ficoll-based or OptiPrep-based density gradients. Islet preparations cultured for 2 days were assessed regarding islet cell viability (fluorescein diacetate/propidium iodide [FDA/PI]), fractional beta-cell viability by FACS, and beta-cell content using iCys. Cytokine/chemokine production from islet preparations was also measured by Bio-plex. After purification, the purity, islet equivalents (IEQ), and islet recovery rates were comparable between the 2 groups. Although FDA/PI and fractional beta-cell viability showed no significant difference, survival of beta cells during culture was significantly higher in the OptiPrep compared with the Ficoll-based density gradient group. There were significantly lower tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, interferon (IFN)-gamma, IL-6, and MIP-1beta productions from the OptiPrep-based density gradient group. OptiPrep-based density gradients reduced cytokine/chemokine production by islet preparations. In addition, OptiPrep-based density gradient purification significantly reduced the loss of beta-cell mass during pretransplantation culture.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19249543      PMCID: PMC3780973          DOI: 10.1016/j.transproceed.2008.10.059

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations.

Authors:  Hirohito Ichii; Luca Inverardi; Antonello Pileggi; R Damaris Molano; Over Cabrera; Alejandro Caicedo; Shari Messinger; Yoshikazu Kuroda; Per-Olof Berggren; Camillo Ricordi
Journal:  Am J Transplant       Date:  2005-07       Impact factor: 8.086

2.  Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes.

Authors:  Bernhard J Hering; Raja Kandaswamy; Jeffrey D Ansite; Peter M Eckman; Masahiko Nakano; Toshiya Sawada; Ippei Matsumoto; Sung-Hee Ihm; Hui-Jian Zhang; Jamen Parkey; David W Hunter; David E R Sutherland
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

3.  Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience.

Authors:  Tatiana Froud; Camillo Ricordi; David A Baidal; Muhammad M Hafiz; Gaston Ponte; Pablo Cure; Antonello Pileggi; Raffaella Poggioli; Hirohito Ichii; Aisha Khan; Jacqueline V Ferreira; Alberto Pugliese; Violet V Esquenazi; Norma S Kenyon; Rodolfo Alejandro
Journal:  Am J Transplant       Date:  2005-08       Impact factor: 8.086

4.  Automated method for isolation of human pancreatic islets.

Authors:  C Ricordi; P E Lacy; E H Finke; B J Olack; D W Scharp
Journal:  Diabetes       Date:  1988-04       Impact factor: 9.461

5.  Five-year follow-up after clinical islet transplantation.

Authors:  Edmond A Ryan; Breay W Paty; Peter A Senior; David Bigam; Eman Alfadhli; Norman M Kneteman; Jonathan R T Lakey; A M James Shapiro
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

  5 in total
  6 in total

1.  Promoting 3-D Aggregation of FACS Purified Thymic Epithelial Cells with EAK 16-II/EAKIIH6 Self-assembling Hydrogel.

Authors:  Asako Tajima; Wen Liu; Isha Pradhan; Suzanne Bertera; Robert A Lakomy; William A Rudert; Massimo Trucco; Wilson S Meng; Yong Fan
Journal:  J Vis Exp       Date:  2016-06-27       Impact factor: 1.355

2.  Antiproinflammatory effects of iodixanol (OptiPrep)-based density gradient purification on human islet preparations.

Authors:  A Mita; C Ricordi; S Messinger; A Miki; R Misawa; S Barker; R D Molano; R Haertter; A Khan; S Miyagawa; A Pileggi; L Inverardi; R Alejandro; B J Hering; H Ichii
Journal:  Cell Transplant       Date:  2010-08-17       Impact factor: 4.064

3.  Evolution of β-Cell Replacement Therapy in Diabetes Mellitus: Islet Cell Transplantation.

Authors:  Cyrus Jahansouz; Cameron Jahansouz; Sean C Kumer; Kenneth L Brayman
Journal:  J Transplant       Date:  2011-10-15

Review 4.  Pig-islet xenotransplantation: recent progress and current perspectives.

Authors:  Hai-Tao Zhu; Wan-Li Wang; Liang Yu; Bo Wang
Journal:  Front Surg       Date:  2014-03-24

5.  Excellent Islet Yields after 18-h Porcine Pancreas Preservation by Ductal Injection, Pancreas Preservation with MK Solution, Bottle Purification, and Islet Purification Using Iodixanol with UW Solution and Iodixanol with MK Solution.

Authors:  Kazuho Kuwae; Chika Miyagi-Shiohira; Eri Hamada; Yoshihito Tamaki; Kai Nishime; Mayuko Sakai; Tasuku Yonaha; Erika Makishi; Issei Saitoh; Masami Watanabe; Hirofumi Noguchi
Journal:  J Clin Med       Date:  2019-09-30       Impact factor: 4.241

6.  Improving Single-Cell Encapsulation Efficiency and Reliability through Neutral Buoyancy of Suspension.

Authors:  Hangrui Liu; Ming Li; Yan Wang; Jim Piper; Lianmei Jiang
Journal:  Micromachines (Basel)       Date:  2020-01-15       Impact factor: 2.891

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.